This biomarker is also known as:
- lectin galactoside-binding soluble 3-binding protein,
- Basement membrane autoantigen p105,
- mac-2 BP,
- galectin-3-binding protein,
- Lectin galactoside-binding soluble 3-binding protein,
- Tumor-associated antigen 90K,
- basement membrane autoantigen p105,
- tumor-associated antigen 90K,
- serum protein 90K,
- Mac-2 BP,
- L3 antigen,
- Mac-2-binding protein,
- lectin, galactoside-binding, soluble, 3 binding protein,
View in BioMuta
LGALS3BP is a secreted protein that binds to a human macrophage-associated lectin known as Mac-2 and also binds galectin 1. Elevated levels of LGALS3BP have been found in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV).
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Average expression of LGALS3BP was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.
LGALS3BP was one of 13 genes out of 50 selected for further validation in PMID:21617380.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.